Stock Events

Stock Events

Neximmune 

€4.55
21
-€0.00-0%Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
4.55
52W Low
4.55
Volume
-
Avg. Volume
0
Mkt Cap
6.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Jan 1Expected
Q4 0
-0.28
0.05
0.39
0.72
Expected EPS
-0.280756
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-29.88MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7370.STU. It's not an investment recommendation.
NVIDIA
5
NVDA
Apple
4
AAPL
Microsoft
4
MSFT
Amazon
4
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. has a strong portfolio in cell therapy and immunotherapy, competing in the same space as Neximmune with its cancer and infectious disease treatments.
Novartis
NVS
Mkt Cap303.67B
Novartis AG has a broad portfolio that includes CAR T-cell therapies and other advanced immunotherapies, making it a competitor in the immunotherapy space.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. has a diverse biotechnology portfolio, including oncology and immunotherapy treatments that compete with Neximmune's offerings.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a leader in cancer immunotherapy with its blockbuster drug Keytruda, competing in the oncology space with Neximmune.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a broad range of immunotherapy and oncology treatments, making it a competitor in the same therapeutic areas as Neximmune.

About

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Show More
CEO
Craig R. Jalbert
Employees
6
Country
United States
ISIN
US65344D2080
WKN
000A3EUTV

Listings

MU
DE
737.MU
STU
DE
7370.STU
STU
DE
737.STU
OTC Link
US
NEXI

0 Comments

Share your thoughts

FAQs

What is Neximmune stock price today?▼
The current price of 7370.STU is €4.55 EUR — it has decreased by -0% in the past 24 hours. Watch Neximmune stock price performance more closely on the chart.
What is Neximmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Neximmune stocks are traded under the ticker 7370.STU.
Is Neximmune stock price growing?▼
7370.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Neximmune has showed a +0% increase.
What is Neximmune market cap?▼
Today Neximmune has the market capitalization of 6.35M
What is Neximmune revenue for the last year?▼
Neximmune revenue for the last year amounts to 0 EUR.
What is Neximmune net income for the last year?▼
7370.STU net income for the last year is -29.88M EUR.
How many employees does Neximmune have?▼
As of November 2, 2026, the company has 6 employees.
In which sector is Neximmune located?▼
Neximmune operates in the Health & Wellness sector.
When did Neximmune complete a stock split?▼
The last stock split for Neximmune was on October 19, 2023 with a ratio of 1:25.
Where is Neximmune headquartered?▼
Neximmune is headquartered in Gaithersburg, United States.